Warning: The NCBI web site requires JavaScript to function. more...
Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-alpha, Oncostatin M and response to biologic therapies.
Moran EM, Mullan R, McCormick J, Connolly M, Sullivan O, Fitzgerald O, Bresnihan B, Veale DJ, Fearon U.
Arthritis Res Ther. 2009;11(4):R113. Epub 2009 Jul 23.
Related citations
Oncostatin M induces angiogenesis and cartilage degradation in rheumatoid arthritis synovial tissue and human cartilage cocultures.
Fearon U, Mullan R, Markham T, Connolly M, Sullivan S, Poole AR, FitzGerald O, Bresnihan B, Veale DJ.
Arthritis Rheum. 2006 Oct;54(10):3152-62.
The effects of 1 alpha,25-dihydroxyvitamin D(3) on matrix metalloproteinase and prostaglandin E(2) production by cells of the rheumatoid lesion.
Tetlow LC, Woolley DE.
Arthritis Res. 1999;1(1):63-70. Epub 1999 Oct 14.
Mast cell activation and its relation to proinflammatory cytokine production in the rheumatoid lesion.
Woolley DE, Tetlow LC.
Arthritis Res. 2000;2(1):65-74.
Matrix metalloproteinase 10 promotion of collagenolysis via procollagenase activation: implications for cartilage degradation in arthritis.
Barksby HE, Milner JM, Patterson AM, Peake NJ, Hui W, Robson T, Lakey R, Middleton J, Cawston TE, Richards CD, Rowan AD.
Arthritis Rheum. 2006 Oct;54(10):3244-53.
Synovial fluid levels of tumor necrosis factor alpha and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen and cartilage aggrecan in rheumatoid arthritis but not in osteoarthritis.
Manicourt DH, Poilvache P, Van Egeren A, Devogelaer JP, Lenz ME, Thonar EJ.
Arthritis Rheum. 2000 Feb;43(2):281-8.
Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis.
Catrina AI, Lampa J, Ernestam S, af Klint E, Bratt J, Klareskog L, Ulfgren AK.
Rheumatology (Oxford). 2002 May;41(5):484-9.
Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
Keyszer G, Lambiri I, Nagel R, Keysser C, Keysser M, Gromnica-Ihle E, Franz J, Burmester GR, Jung K.
J Rheumatol. 1999 Feb;26(2):251-8.
Oncostatin M in combination with tumor necrosis factor alpha induces cartilage damage and matrix metalloproteinase expression in vitro and in vivo.
Hui W, Rowan AD, Richards CD, Cawston TE.
Arthritis Rheum. 2003 Dec;48(12):3404-18.
Increased CD40 expression on articular chondrocytes from patients with rheumatoid arthritis: contribution to production of cytokines and matrix metalloproteinases.
Gotoh H, Kawaguchi Y, Harigai M, Hara M, Saito S, Yamaguchi T, Shimada K, Kawamoto M, Tomatsu T, Kamatani N.
J Rheumatol. 2004 Aug;31(8):1506-12.
Osteoarthritis and rheumatoid arthritis pannus have similar qualitative metabolic characteristics and pro-inflammatory cytokine response.
Furuzawa-Carballeda J, Macip-Rodríguez PM, Cabral AR.
Clin Exp Rheumatol. 2008 Jul-Aug;26(4):554-60.
Relative contribution of matrix metalloprotease and cysteine protease activities to cytokine-stimulated articular cartilage degradation.
Sondergaard BC, Henriksen K, Wulf H, Oestergaard S, Schurigt U, Bräuer R, Danielsen I, Christiansen C, Qvist P, Karsdal MA.
Osteoarthritis Cartilage. 2006 Aug;14(8):738-48. Epub 2006 Mar 23.
The role of oncostatin M in animal and human connective tissue collagen turnover and its localization within the rheumatoid joint.
Cawston TE, Curry VA, Summers CA, Clark IM, Riley GP, Life PF, Spaull JR, Goldring MB, Koshy PJ, Rowan AD, Shingleton WD.
Arthritis Rheum. 1998 Oct;41(10):1760-71.
Suppressive effect of secretory phospholipase A2 inhibitory peptide on interleukin-1beta-induced matrix metalloproteinase production in rheumatoid synovial fibroblasts, and its antiarthritic activity in hTNFtg mice.
Thwin MM, Douni E, Arjunan P, Kollias G, Kumar PV, Gopalakrishnakone P.
Arthritis Res Ther. 2009;11(5):R138. Epub 2009 Sep 18.
Oncostatin M stimulates monocyte chemoattractant protein-1- and interleukin-1-induced matrix metalloproteinase-1 production by human synovial fibroblasts in vitro.
Langdon C, Leith J, Smith F, Richards CD.
Arthritis Rheum. 1997 Dec;40(12):2139-46.
In vitro model for the analysis of synovial fibroblast-mediated degradation of intact cartilage.
Pretzel D, Pohlers D, Weinert S, Kinne RW.
Arthritis Res Ther. 2009;11(1):R25. Epub 2009 Feb 18.
The role of cytokines in osteoarthritis pathophysiology.
Fernandes JC, Martel-Pelletier J, Pelletier JP.
Biorheology. 2002;39(1-2):237-46. Review.
The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases, and other destructive and inflammatory responses in osteoarthritis.
Bondeson J, Wainwright SD, Lauder S, Amos N, Hughes CE.
Arthritis Res Ther. 2006;8(6):R187.
Interleukin 17 levels are increased in juvenile idiopathic arthritis synovial fluid and induce synovial fibroblasts to produce proinflammatory cytokines and matrix metalloproteinases.
Agarwal S, Misra R, Aggarwal A.
J Rheumatol. 2008 Mar;35(3):515-9. Epub 2008 Jan 15.
Preferential induction of prodestructive matrix metalloproteinase-1 and proinflammatory interleukin 6 and prostaglandin E2 in rheumatoid arthritis synovial fibroblasts via tumor necrosis factor receptor-55.
Alsalameh S, Amin RJ, Kunisch E, Jasin HE, Kinne RW.
J Rheumatol. 2003 Aug;30(8):1680-90.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on